JP2018168169A5 - - Google Patents

Download PDF

Info

Publication number
JP2018168169A5
JP2018168169A5 JP2018111642A JP2018111642A JP2018168169A5 JP 2018168169 A5 JP2018168169 A5 JP 2018168169A5 JP 2018111642 A JP2018111642 A JP 2018111642A JP 2018111642 A JP2018111642 A JP 2018111642A JP 2018168169 A5 JP2018168169 A5 JP 2018168169A5
Authority
JP
Japan
Prior art keywords
cancer
disease
pharmaceutically acceptable
cell carcinoma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018111642A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018168169A (ja
JP6553772B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018168169A publication Critical patent/JP2018168169A/ja
Publication of JP2018168169A5 publication Critical patent/JP2018168169A5/ja
Application granted granted Critical
Publication of JP6553772B2 publication Critical patent/JP6553772B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018111642A 2013-03-15 2018-06-12 ピリミド−ジアゼピノン化合物および障害の治療方法 Active JP6553772B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361802075P 2013-03-15 2013-03-15
US61/802,075 2013-03-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016503457A Division JP6553589B2 (ja) 2013-03-15 2014-03-17 ピリミド−ジアゼピノン化合物および障害の治療方法

Publications (3)

Publication Number Publication Date
JP2018168169A JP2018168169A (ja) 2018-11-01
JP2018168169A5 true JP2018168169A5 (cg-RX-API-DMAC7.html) 2019-07-11
JP6553772B2 JP6553772B2 (ja) 2019-07-31

Family

ID=51538565

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016503457A Active JP6553589B2 (ja) 2013-03-15 2014-03-17 ピリミド−ジアゼピノン化合物および障害の治療方法
JP2018111642A Active JP6553772B2 (ja) 2013-03-15 2018-06-12 ピリミド−ジアゼピノン化合物および障害の治療方法
JP2019125063A Pending JP2019206534A (ja) 2013-03-15 2019-07-04 ピリミド−ジアゼピノン化合物および障害の治療方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016503457A Active JP6553589B2 (ja) 2013-03-15 2014-03-17 ピリミド−ジアゼピノン化合物および障害の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019125063A Pending JP2019206534A (ja) 2013-03-15 2019-07-04 ピリミド−ジアゼピノン化合物および障害の治療方法

Country Status (5)

Country Link
US (4) US9676792B2 (cg-RX-API-DMAC7.html)
EP (4) EP2970317A4 (cg-RX-API-DMAC7.html)
JP (3) JP6553589B2 (cg-RX-API-DMAC7.html)
CA (1) CA2902599C (cg-RX-API-DMAC7.html)
WO (1) WO2014145909A2 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970317A4 (en) * 2013-03-15 2016-11-02 Dana Farber Cancer Inst Inc PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES
BR112017003651A2 (pt) * 2014-09-02 2017-12-05 Pf Medicament derivados de isoquinolinona úteis no tratamento de câncer
CN104803914B (zh) * 2015-03-05 2017-11-14 成都理工大学 作为Rho激酶抑制剂的六氢氮杂卓氧基苯甲酰胺类化合物
EP3307069B1 (en) * 2015-06-10 2021-08-04 Hackensack University Medical Center Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
JP2019512459A (ja) * 2016-03-04 2019-05-16 アンホイ ニュー スター ファーマシューティカル デベロップメント カンパニー,リミテッド 7員環化合物、その調製方法、その医薬組成物、およびその使用
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
EA038531B1 (ru) * 2016-03-25 2021-09-10 Аб Сьянс Способ лечения амиотрофного латерального склероза, применение фармацевтической композиции, содержащей мазитиниб
AU2017248186B2 (en) * 2016-04-07 2021-10-21 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating PI3K-mediated disorders
PT3472153T (pt) 2016-06-16 2021-12-31 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
CA3040173A1 (en) * 2016-10-18 2018-04-26 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating dclk1/2-mediated disorders
JP7394623B2 (ja) 2016-11-02 2023-12-08 ノバルティス アーゲー Fgfr4インヒビターおよび胆汁酸捕捉薬の組合せ
SG11201908234WA (en) * 2017-02-24 2019-10-30 Daegu Gyeongbuk Medical Innovation Found Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer
US10298137B2 (en) * 2017-03-10 2019-05-21 Semiconductor Components Industries, Llc Advanced frequency reduction of quasi-resonant converters
AU2018392805A1 (en) 2017-12-22 2020-05-07 Dana-Farber Cancer Institute, Inc. NEK inhibitors and methods of use
US20210333285A1 (en) * 2018-04-13 2021-10-28 The Regents Of The University Of California Detection of phosphokinase signatures
JP7201800B2 (ja) * 2018-09-30 2023-01-10 メッドシャイン ディスカバリー インコーポレイテッド Flt3およびaxlの阻害剤としての3,9-ジアザスピロ[5,5]ウンデカン系化合物
CN111039944B (zh) * 2018-10-12 2021-11-23 中国科学院合肥物质科学研究院 Mst1激酶抑制剂及其用途
CN109824678B (zh) * 2019-03-20 2020-06-19 浙江大学 一种氮杂卓吲哚类生物碱及制备和抗疟疾用途
WO2020206608A1 (en) 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
US12365696B2 (en) 2019-05-10 2025-07-22 Dana-Farber Cancer Institute, Inc. Small-molecule focal adhesion kinase (FAK) inhibitors
AU2020300619A1 (en) * 2019-07-03 2022-01-27 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
US20220280530A1 (en) * 2019-08-08 2022-09-08 Anhui Newstar Pharmaceutical Development Co., Ltd. Prevention or treatment of diseases and disorders associated with tissue damage
KR102498531B1 (ko) * 2020-06-29 2023-02-13 한국과학기술연구원 단백질 카이네이즈 trkc에 선택적인 억제제로서의 신규 피리미도디아제핀 유도체
WO2022061019A1 (en) * 2020-09-16 2022-03-24 Collaborations Pharmaceuticals, Inc. The antiviral drug tilorone is a potent and selective inhibitor of acetylcholinesterase
EP4229061A4 (en) * 2020-10-14 2024-09-25 Ranok Therapeutics (Hangzhou) Co. Ltd. METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION
EP4238974A4 (en) * 2020-10-28 2024-10-23 Adlai Nortye Biopharma Co., Ltd. HIGH ACTIVITY WNT PATHWAY INHIBITOR COMPOUND
US20240091226A1 (en) * 2021-01-05 2024-03-21 Sumitomo Pharma Oncology, Inc. Forms and Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitor
US12577253B2 (en) 2021-02-08 2026-03-17 Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. 5,6-dihydrothieno[3,4-h]quinazoline compound
TW202321244A (zh) * 2021-07-26 2023-06-01 大陸商杭州阿諾生物醫藥科技有限公司 一種Wnt通路抑制劑化合物
WO2023055827A1 (en) * 2021-09-30 2023-04-06 Crinetics Pharmaceuticals, Inc. Parathyroid hormone (pth) receptor antagonists and uses thereof
CN114478539B (zh) * 2022-02-09 2024-02-02 中国人民解放军海军军医大学 一种新型dclk1抑制剂及其制备方法和应用
CN115877004B (zh) * 2022-08-09 2024-12-20 重庆大学 一种taok3抑制剂以及taok3及其抑制剂在调控天然免疫系统中的应用
CN116173040B (zh) * 2022-08-23 2025-05-23 杭州天玑济世生物科技有限公司 Xmd17109作为arih1激动剂的用途
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment
CN121154824A (zh) * 2025-11-19 2025-12-19 安徽省立医院(中国科学技术大学附属第一医院) Nuak1作为生物标志物在骨质疏松临床诊断和预防中的应用及其试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE479434T1 (de) 2006-02-14 2010-09-15 Vertex Pharma Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
CN101636399B (zh) * 2007-03-22 2012-04-18 武田药品工业株式会社 可用作plk1抑制剂的取代的嘧啶并二氮杂*
CN101878216B (zh) 2007-09-28 2013-07-10 西克拉塞尔有限公司 作为蛋白激酶抑制剂的嘧啶衍生物
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
GB201205752D0 (en) * 2012-03-30 2012-05-16 Cyclacel Ltd Treatment
EP2970317A4 (en) * 2013-03-15 2016-11-02 Dana Farber Cancer Inst Inc PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES

Similar Documents

Publication Publication Date Title
JP2016515537A5 (cg-RX-API-DMAC7.html)
JP2022137047A5 (cg-RX-API-DMAC7.html)
JP2022544189A5 (cg-RX-API-DMAC7.html)
JP2019514883A5 (cg-RX-API-DMAC7.html)
US7923554B2 (en) HIV inhibiting 1,2,4-triazin-6-one derivatives
CN103200822B (zh) 2-取代-8-烷基-7-氧代-7,8-二氢吡啶并[2,3-d]嘧啶-6-腈和其应用
JP4491231B2 (ja) 2,4,5−三置換チアゾリル誘導体およびそれらの抗炎症活性
JP2021519779A5 (cg-RX-API-DMAC7.html)
FI4212529T3 (fi) Heterosyklisiä yhdisteitä immunomodulaattoreina
JP5008567B2 (ja) Hiv阻害性5−ヘテロシクリルピリミジン
JP2019514876A5 (cg-RX-API-DMAC7.html)
JP2019514882A5 (cg-RX-API-DMAC7.html)
JP2010526069A5 (cg-RX-API-DMAC7.html)
JP2018515490A5 (cg-RX-API-DMAC7.html)
JP2010524930A5 (cg-RX-API-DMAC7.html)
JP2019519587A5 (cg-RX-API-DMAC7.html)
JP2017537946A5 (cg-RX-API-DMAC7.html)
JP2016523973A5 (cg-RX-API-DMAC7.html)
JP2011510068A5 (cg-RX-API-DMAC7.html)
JP2008517978A (ja) Hiv阻害性二環式ピリミジン誘導体
JP2024511996A5 (cg-RX-API-DMAC7.html)
HUP0401346A2 (hu) HIV-gátló pirimidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
JP2013545812A5 (cg-RX-API-DMAC7.html)
KR20080114741A (ko) Hiv를 억제하는 5-아미도 치환 피리미딘
JP2022535577A5 (cg-RX-API-DMAC7.html)